Site map
Posts
- Using spectroscopy to recognize secondary-progressive MS patients
- $28 million USD investment for new research
- 2014 McDonald Fellowships announced
- 2016 McDonald Fellowships and Du Pré Grantees announced
- 23 answers on predicting disease progression and MRI
- 400 young people gather in Rome to learn about MS
- 45% of people with MS have experienced prejudice in the UK
- 7th Russian patients congress
- A diet with high salt intake can worsen MS course
- A new fingolimod-like drug is safe in people with relapsing-remitting MS
- A new gene target for progressive MS
- A new job for Eliana
- A non-invasive method to identify MS progression
- A simple specialised eye examination can show the effect of MS drugs
- A specialized eye test can predict disease progression in MS
- Abdel visits the Lebanese MS Friends Society
- ABEM works with Brazilian mental health initiative
- Accessible fashion in Germany
- AEDEM COCEMFE launches program to support people at home
- Ageing and MS in Australia
- ALCEM becomes supporting organisation
- Alemtuzumab vs interferon in relapsing remitting MS
- Alliance announces first round of grants
- Alternative to natalizumab in people at risk of a brain infection
- Amalia wins Evelyn Nicholson Award
- An appropriate way of measuring progression in clinical trials
- Applications for MSIF fellowships and grants now open
- Archive of Tawasol issues now available
- Are brain lesions related to sexual dysfunction in women with MS?
- ARSEP is working with photographer Dorothy Shoes to exhibit her work on MS
- ARSEP joins MS International Federation
- Avoiding post-partum MS worsening
- Awareness raising in Lebanon
- Better test for risk of PML infection in Natalizumab patients
- Bigger brains can protect against physical disability
- Biomarker for predicting MS risk after clinically isolated syndrome
- Biomarkers of inflammation in progressive MS
- Biomarkers of spinal cord injury
- Breaking down the barriers
- Can Melatonin improve MS?
- Can specialised eye assessments monitor MS activity and attacks?
- Canada trial for stem cell therapy
- Canadian MS Society meets 75 MPs in 2 days
- Cast your vote
- CCSVI: Latest findings show no association to multiple sclerosis
- Cervical cord damage and disability in MS
- Changes in thalamus as a measure of progression in MS
- Characteristics of primary progressive MS
- Chopsticks and capacity-building in Chengdu
- Coffee consumption and risk of multiple sclerosis
- Cognitive impairment and sodium concentration in gray matter
- Cognitive rehabilitation in MS
- Consecutive pregnancies in MS
- Consultant wanted: evidence review on quality of life & MS
- Controversial results from a new vitamin D study
- Could gut microbes play a role in MS?
- Creative healing: how creative pursuits can help ease symptoms of MS
- Cycling the Tour de France Mountains to end MS
- Delaying the development of secondary progressive MS
- Different activation of the immune system in types of MS
- Disappointing results from fingolimod trial in primary progressive MS
- Disease-modifying drugs may reduce disability progression in relapsing-remitting MS
- DMSG launches app to help with cognition
- Does ethnicity play a role in neuromyelitis optica (NMO)?
- Does season of birth contribute to the risk of developing MS in the UK?
- Early detection of nerve damage using the retina
- Early evidence of multiple sclerosis in high risk family members
- Early identification of progressive multifocal leukoencephalopathy in patients on natalizumab
- Early treatment benefits individuals with a first attack resembling MS
- ECTRIMS support for joint McDonald fellowship
- Effectiveness of memory rehabilitation in people with MS
- Effects of an immune system gene on MS subtypes and MRI
- EMSP and RIMS social media conference
- EMSP Spring Conference: Growing with MS
- Epilepsy drug could protect nerves from damage in MS
- Evelyn Nicholson International Caregiver award 2016
- Exclusive breastfeeding is safe following childbirth
- Exploring the relationship between HIV and MS
- Fingolimod is not effective in primary progressive multiple sclerosis
- Fingolimod safety and efficacy confirmed
- First treatment licensed for primary progressive MS in the US
- Flee or fight?
- Further evidence for a brain region involved in fatigue in MS
- Further evidence for effectiveness of alemtuzumab
- Future MS treatments
- Geographical latitude and the onset of MS
- German MS Society launches family planning telephone counselling service
- Get Wet for MS makes a splash in Spain
- Giancarlo Comi wins Charcot Award
- Global Patient Solidarity Day & UN Day for people with Disabilities
- Good news for people with MS in Poland
- Hand in hand with people affected by MS
- Hematopoietic stem cell treatment in MS
- Hematopoietic stem cells and MS
- Highlights from the ‘Living with MS Day’
- Home-based exercises could reduce risk of falls in MS
- Hormonal treatment improves MS relapses in women
- Hormone replacement therapy could improve physical quality of life for women with MS
- Improving clinical trial designs in MS
- Improving diagnosis of MS
- Improving fatigue by doing exercise
- Improving quality of life for people with MS
- Improving walking with nabiximols: new findings
- Inclusive bathing beach in Russia
- Independence is top concern as people age with MS
- India celebrates MS activist for International Women’s Day
- Infections and MS: new evidence
- Influence of ethnicity on disease progression
- International Day for Persons with Disabilities
- International Progressive MS Alliance funds global research collaboration
- Interview with Mauricio Farez
- Intrathecal Rituximab is not effective in progressive multiple sclerosis
- Investigating cognition to fully assess MS progression
- Israel MS Society expands its support network
- Israeli summer camp for children who have a parent with MS
- Japan MS Society’s sixth MS Seminar
- Kiss Goodbye to MS goes global
- Kiss Goodbye to MS launches
- Kuwaiti MS Association organises first Gulf forum
- Latest MS research highlighted at French conference
- Lifestyle risk factors in the progression of multiple sclerosis
- Long term support for MSIF’s Du Pré Grants from the Netherlands
- Long-term effects of early treatment in people with MS
- Long-term efficacy, safety and tolerability of fingolimod
- Long-term evolution of MS disability in the treatment era
- Long-term outcomes after HSCT for MS
- Long-term safety and effectiveness of fampridine
- Magyar SM Társaság hosts two-day workshop
- Make Medications Accessible
- Maurice Maso wins Evelyn Nicholson Award
- Middle East volunteers trained in MS counselling
- Misdiagnosis of MS
- Mitoxantrone and risk of cancer in MS
- Month of the caregiver in India
- More Du Pré Grants for 2014 announced
- Morocco consultancy opportunity
- MS Australia marks national caregivers week with a “thank you”
- MS Awareness Soars in the Americas
- MS Force in Portugal
- MS Frontiers 2015: Research Roundup
- MS Helpline celebrates 25 years of supporting people affected by MS in the UK
- MS in focus on ageing
- MS International Federation announces first wave of 2014 Du Pré Grants
- MS International Federation launches Arabic e-newsletter
- MS International Federation launches new website
- MS International Federation launches programme in the Arab region
- MS International Federation to update the Principles for Quality of Life
- MS Ireland takes action
- MS on Russian TV
- MS Queensland runs world’s first slide for MS!
- MS Society of India raises awareness in Surat
- MS Summer camp: Feels like coming home
- MSIF and ECTRIMS hold first joint alumni event
- MSIF at MENACTRIMS
- MSIF endorses recommendations on early intervention
- MSIF in Latin America
- MSIF is seeking a Research Insight Analyst
- MSIF staff celebrate World MS Day
- MSSI Chennai’s Ann Gonsalvez receives award
- Multiple Sclerosis Ireland launches report on the hidden costs of MS
- Natalizumab improves walking in relapsing-remitting MS
- Natalizumab is more effective than fingolimod in reducing relapses
- Neonatal vitamin D and the risk of MS
- Neurofilament is related to disability and brain shrinkage in MS
- New biomarkers to predict progression in MS
- New drug ozanimod could be an effective alternative to fingolimod
- New drug tested for relapsing-remitting MS
- New educational comic for children
- New markers to stop inflammation in multiple sclerosis
- New publication explains the latest understanding of MS in children
- New report shows MS more prevalent than previously thought
- New target for understanding secondary progressive MS
- New treatment for fatigue
- New treatment for spasticity and pain
- New type of interferon has fewer side effects
- New video showcases the potential of musical neurorehabilitation in Israel
- No link between NR1H3 p.Arg415Gln and multiple sclerosis risk
- No link between oral contraceptive drugs and MS relapses
- No target met unless met for all
- Obesity and MS
- Oceans of Hope reaches Panama
- Official launch of the New Zealand Multiple Sclerosis Research Trust
- Online cognitive training in Germany
- Optical Coherence Tomography (OCT) as a possible biomarker in MS
- Oral steroids as good as intravenous in treating relapses
- Our approach to translation
- Paid internships for people with MS
- People affected by MS helping to steer research in progressive MS
- Phase one of European Register for MS completed
- Physician-assisted death in multiple sclerosis
- Physiotherapy to reduce fatigue and improve balance
- Polish push for Brain Health in MS
- Polish ‘Symphony of Hearts’ shows people what it’s like to experience symptoms of MS
- Portuguese Politicians experience MS symptoms
- Positive outcomes in changing from interferon to glatiramer acetate
- Positive results for people with primary progressive MS
- Practical employment resources in Ireland
- Predicting long-term disability in MS
- Predictive factors for developing MS
- Progressive MS Alliance expands
- Progressive MS Alliance seeks lay members for Scientific Steering Committee
- Progressive MS and disease-modifying drugs
- Progressive MS meeting in Milan
- Pros and cons of alemtuzumab
- Quizzing election candidates about MS
- Radiologically isolated syndrome (RIS) and primary progressive multiple sclerosis (PPMS)
- Radiologically isolated syndrome can help us understand MS
- Rebound syndrome after stopping fingolimod
- Recommended treatment after stopping natalizumab
- Recruitment complete for new progressive MS drug trial
- Regulatory T Cells promote remyelination
- Research highlights of 2016
- Resources for caregivers
- Results from a long-term observational study on MS
- Results of our cognition and MS survey
- Rituximab in multiple sclerosis
- Running, biking and hiking for MS
- Safety and efficacy of siponimod for relapsing-remitting MS
- Second Scientific Congress of the International Progressive MS Alliance
- Services and celebration in India
- Sex-specific differences in comorbid conditions in MS
- Sexual dysfunction is common in MS
- Shift.MS launches tool to give online Cognitive Behavioural Therapy
- Simple adjustments could keep people with MS in work
- Six months to World MS Day
- Smoking worsens MS
- Social cognition in multiple sclerosis
- Spanish professionals trained in emotional health
- Special visit marks launch of MSIF’s capacity building programme in Morocco
- Spinal cord and retinal abnormalities correlate with disability
- Spinal cord is affected early in primary progressive MS
- Stem cell treatment halts MS progression
- Stephen Hauser wins Charcot Award
- Steroids, mobility and osteoporosis
- Strengthening the MS movement in China
- Study group reports on clinical trials in children with MS
- Swedish government to develop national guidelines
- Switching to second-line disease-modifying drugs
- Take part in the global MS employment survey
- Take the Pledge
- Tawasol – December 2016 issue
- Tawasol – March 2017 issue
- The effect of salt intake on MS relapses in children
- The National MS Society joins forces with the MS Society of Bermuda
- The role deep grey matter in the brain plays in MS
- The role of gut microbes in multiple sclerosis
- The role of iron and brain damage in MS
- The world unites to Kiss Goodbye to MS
- Training MS organisations in the Arab region
- Treat Me Right campaign changes UK guidelines
- Trigeminal neuralgia and fampridine: further contraindication
- UN looks past 2015
- Underweight women on fingolimod at higher risk of lymphopenia
- Uninterrupted – personal stories about the realities of MS
- Universal access declaration reaches 88,000 signatures
- Use of metabolic syndrome drugs in multiple sclerosis
- Vacancy: Head of Research and Access
- Vitamin D and early onset of MS
- Vitamin D and neural stem cells
- What happened at ECTRIMS 2015?
- What happened at ECTRIMS 2016?
- Winner of 2013 James D Wolfensohn award announced
- Wolfensohn Award 2015
- Wolfensohn Award 2017
- Working with MS Home in China
- World MS Day 2015
- World MS Day 2017
- World MS Day across the globe
- World MS Day is around the corner…
- World MS Day is coming
- World MS Day launches on 15 April
- World MS Day makes an impact across the globe
- World MS Day website goes live
- Your chance to ask a young researcher about his work
- €12.6 million awarded to 3 projects in global effort to end progressive MS
Pages
- About MS
- About us
- Advocacy
- Annual accounts and reviews
- How we are governed
- International MS awards
- Our income sources in 2016
- Our members
- Our staff
- Supporting MS organisations
- Who we are and what we do
- Associate membership benefits
- Associate membership criteria
- Cast your vote
- Contact us
- Donate
- Full membership benefits
- Full membership criteria
- Get involved
- Global MS Employment survey 2010
- Home
- How we are funded
- How we work with the healthcare industry
- Living with MS
- Member login
- News & Events
- Page not found
- Registration submitted
- Research
- Resources
- Seven principles to improve quality of life
- Sign up for news on Kiss Goodbye to MS
- Site map
- Supporting organisation benefits
- Supporting organisation criteria
- Take the MSIF Arab region quiz
- Terms and privacy